Generalist in allogeneic hematopoietic stem cell transplantation for MDS or AML: Epigenetic therapy.
Generalist in allogeneic hematopoietic stem cell transplantation for MDS or AML: Epigenetic therapy.
复制标题
异基因造血干细胞移植治疗 MDS 或 AML 的多面手：表观遗传疗法
DOI：
10.3389/fimmu.2022.1034438
复制
发表时间：
2022
影响因子：
7.3
通讯作者：
中科院分区：
文献类型：
--
作者：
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains the only curative treatment for patients with myeloid malignancies such as myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). However, relapse and graft-versus-host disease (GvHD) still affect the survival of patients who receive allo-HSCT, and more appropriate therapeutic strategies should be applied at all stages of transplantation to prevent these adverse events. The use of epigenetics agents, such as hypomethylating agents (HMAs), has been explored to decrease the risk of relapse by epigenetic modulation, which is especially effective among AML patients with poor mutations in epigenetic regulators. Furthermore, epigenetic agents have also been regarded as prophylactic methods for GvHD management without abrogating graft versus leukemia (GvL) effects. Therefore, the combination of epigenetic therapy and HSCT may optimize the transplantation process and prevent treatment failure. Existing studies have investigated the feasibility and effectiveness of using HMAs in the pretransplant, transplant and posttransplant stages among MDS and AML patients. This review examines the application of HMAs as a bridge treatment to reduce the tumor burden and the determine appropriate dose during allo-HSCT. Within this review, we also examine the efficacy and safety of HMAs alone or HMA-based strategies in posttransplant settings for MDS and AML. Finally, we provide an overview of other epigenetic candidates, which have been discussed in the nontransplant setting.
登录
查看更多内容
DOI：
10.1016/j.bbmt.2015.09.004
发表时间：
2016-02
期刊：
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
影响因子：
--
作者：
Craddock C;Jilani N;Siddique S;Yap C;Khan J;Nagra S;Ward J;Ferguson P;Hazlewood P;Buka R;Vyas P;Goodyear O;Tholouli E;Crawley C;Russell N;Byrne J;Malladi R;Snowden J;Dennis M
通讯作者：
Dennis M
DOI：
10.1016/j.hoc.2010.02.003
发表时间：
2010-04
期刊：
Hematology/oncology clinics of North America
影响因子：
--
作者：
Bartenstein M;Deeg HJ
通讯作者：
Deeg HJ
影响因子：
4.7
作者：
Ciotti G;Marconi G;Martinelli G
通讯作者：
Martinelli G
影响因子：
20.3
作者：
Fehniger, Todd A.;Uy, Geoffrey L.;Vij, Ravi
通讯作者：
Vij, Ravi
影响因子：
12.4
作者：
Dittman, Jessica;Haydn, Tinka;Fulda, Simone
通讯作者：
Fulda, Simone